AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
thiabendazole 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| anthelminthics, tiabendazole derivatives | 2621 | 148-79-8 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
2-Substituted benzimidazole first introduced in 1962. It is active against a variety of nematodes and is the drug of choice for STRONGYLOIDIASIS. It has CENTRAL NERVOUS SYSTEM side effects and hepatototoxic potential. (From Smith and Reynard, Textbook of Pharmacology, 1992, p919)
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 3 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 0.05 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 0.10 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 212.95 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 2.321 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 0.705 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 76.033 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 95.060 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 29.370 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 42.850 | % | High | 1 |
| herg | hERG pIC50 | 4.001 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 13.274 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 158.489 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 9.860 | % | High | 1 |
| kinase-safety-class | ACVR2A,ACVR2B,ALK,AURKA,AURKB,AXL,BRAF,CAMK2B,CAMK2D,CDK1,CDK5,CDK9,CHEK1,DDR1,DYRK1B,EIF2AK3,ERBB2,FLT3,GRK2,GSK3B,IRAK1,ITK,JAK1,JAK2,MAP3K1,MAP3K10,MAP3K11,MAP3K21,MAP3K7,MAP4K1,MAP4K3,MAPK10,MAPK7,MAPK9,MARK4,MELK,MTOR,NTRK2,PDK4,PDPK1,PIM2,PRKCD,PRKDC,SGK1,SIK2,SIK3,STK33,SYK,TEK,TTK,ULK1 | 51 | |||
| kinase-selectivity-class | ACVR2A,ACVR2B,CAMK2D,DYRK1B,MAP2K3,MAP2K6,MAP3K10,MAP3K21,MARK4,SIK2,STK33,TTK | 12 | |||
| mdck-mdr1-bcrp-efflux | MDCK-MDR1-BCRP efflux ratio | 0.682 | High | 1 | |
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 1.211 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 196.336 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 27 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 0.423 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 20.640 | % | High | 1 |
| rat-kpuu-brain | Rat brain Kpuu | 0.925 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 30.974 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 86.510 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 16.320 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 257.632 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| April 7, 1967 | FDA |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | D01AC06 | DERMATOLOGICALS ANTIFUNGALS FOR DERMATOLOGICAL USE ANTIFUNGALS FOR TOPICAL USE Imidazole and triazole derivatives |
| ATC | P02CA02 | ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS ANTHELMINTICS ANTINEMATODAL AGENTS Benzimidazole derivatives |
| FDA EPC | N0000175481 | Anthelmintic |
| MeSH PA | D000871 | Anthelmintics |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000977 | Antiparasitic Agents |
| CHEBI has role | CHEBI:35443 | anthelminthic drug |
| CHEBI has role | CHEBI:35444 | antinematodal drug |
| CHEBI has role | CHEBI:86328 | antifungal agrochemical |
Related Drugs by ATC class:
D01AC Imidazole and triazole derivatives 20 drugs
P02CA Benzimidazole derivatives 6 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Infection by Strongyloides | indication | 1214006 | DOID:10955 |
| Ascariasis | indication | 2435008 | DOID:456 |
| Trichuriasis | indication | 3752003 | |
| Cutaneous larva migrans | indication | 19362000 | |
| Infection by larvae of Trichinella spiralis | indication | 88264003 | |
| Enterobiasis | indication | 266162007 | |
| Infection due to Toxocara | indication | 406619001 | |
| Infection by Uncinaria | indication | 414490001 | |
| Ancylostoma Duodenale Infection | indication | ||
| Necator Americanus Infection | indication | ||
| Trichostrongyliasis | off-label use | 33710003 | DOID:1254 |
| Capillaria infection | off-label use | 52979002 | DOID:12474 |
| Infection by Baylisascaris | off-label use | 91156005 | |
| Infection by Dracunculus medinensis | off-label use | 396334002 | DOID:14418 |
| Hepatic failure | contraindication | 59927004 | |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Liver function tests abnormal | contraindication | 166603001 |
🐶 Veterinary Drug Use
| Species | Use | Relation |
|---|---|---|
| Cattle | Infections of Cooperia species | Indication |
| Cattle | Control of infections of gastrointestinal roundworms, Trichostrongylus species | Indication |
| Cattle | Control of infections of gastrointestinal roundworms, Haemonchus species | Indication |
| Cattle | Control of infections of gastrointestinal roundworms, Nematodirus species | Indication |
| Cattle | Control of infections of gastrointestinal roundworms, Ostertagia species | Indication |
| Cattle | Control of infections of gastrointestinal roundworms, Oesophagostomum radiatum | Indication |
| Horses | Control of large and small strongyles | Indication |
| Horses | Control of strongyloides | Indication |
| Horses | Control of pinworms of the genera Strongylus | Indication |
| Horses | Control of pinworms of the genera Cyathostomum Strongylus | Indication |
| Horses | Indication | |
| Horses | Control of pinworms of the genera Cylicobrachytus | Indication |
| Horses | Control of pinworms of the genera Craterostomum | Indication |
| Horses | Control of pinworms of the genera Oesophagodontus | Indication |
| Horses | Control of pinworms of the genera Poteriostomum | Indication |
| Horses | Control of pinworms of the genera Oxyuris | Indication |
| Horses | Control of pinworms of the genera Strongyloides | Indication |
| Horses | Control of ascarids of the genus Parascaris | Indication |
| Goats | Infections of gastrointestinal roundworms, Trichostrongylus species | Indication |
| Goats | Infections of gastrointestinal roundworms, Haemonchus species | Indication |
| Goats | Infections of gastrointestinal roundworms, Ostertagia species | Indication |
| Goats | Infections of gastrointestinal roundworms, Cooperia species | Indication |
| Goats | Infections of gastrointestinal roundworms, Nematodirus species | Indication |
| Goats | Infections of gastrointestinal roundworms, Bunostomom species | Indication |
| Goats | Infections of gastrointestinal roundworms, Strongyloides species | Indication |
| Goats | Infections of gastrointestinal roundworms, Chabertia species | Indication |
| Goats | Infections of gastrointestinal roundworms, Oesophagostomum species | Indication |
| Pheasants | Treatment of gapeworms, Syngamus trachea | Indication |
| Sheep | Infections of gastrointestinal roundworms, Trichostrongylus species | Indication |
| Sheep | Infections of gastrointestinal roundworms, Haemonchus species | Indication |
| Sheep | Infections of gastrointestinal roundworms, Ostertagia species | Indication |
| Sheep | Infections of gastrointestinal roundworms, Cooperia species | Indication |
| Sheep | Infections of gastrointestinal roundworms, Nematodirus species | Indication |
| Sheep | Infections of gastrointestinal roundworms, Bunostomom species | Indication |
| Sheep | Infections of gastrointestinal roundworms, Strongyloides species | Indication |
| Sheep | Infections of gastrointestinal roundworms, Chabertia species | Indication |
| Sheep | Infections of gastrointestinal roundworms, Oesophagostomum species | Indication |
| Swine | Prevention of infections of large roundworms, (genus Ascaris) | Indication |
🐶 Veterinary products
| Product | Applicant | Ingredients |
|---|---|---|
| Thibenzole Sheep & Goat Wormer | Boehringer lngelheim Animal Health USA Inc. | 1 |
| Equizole Horse Wormer | Boehringer lngelheim Animal Health USA Inc. | 1 |
| Thibenzole 20% Swine Premix | Boehringer lngelheim Animal Health USA Inc. | 1 |
| Omnizole | Boehringer lngelheim Animal Health USA Inc. | 1 |
| TBZ Cattle Wormer (Drench) | Boehringer lngelheim Animal Health USA Inc. | 1 |
| TBZ 200 Medicated Feed Premix | Boehringer lngelheim Animal Health USA Inc. | 1 |
| Thibenzole (18 mg) | Boehringer lngelheim Animal Health USA Inc. | 1 |
| E-Z-EX Wormer Pellets | ADM Animal Nutrition | 1 |
| Equizole | Boehringer lngelheim Animal Health USA Inc. | 1 |
| Thibenzole Pig Wormer | Boehringer lngelheim Animal Health USA Inc. | 1 |
| Equizole A | Boehringer lngelheim Animal Health USA Inc. | 2 |
| Tresaderm Dermatologic Solution | Boehringer lngelheim Animal Health USA Inc. | 3 |
| E-Z-EX Wormer Mintrate Block | ADM Animal Nutrition | 1 |
| Thibenzole 300 Medicated | Boehringer lngelheim Animal Health USA Inc. | 1 |
| Equizole Horse Wormer Pellets | Boehringer lngelheim Animal Health USA Inc. | 1 |
| Equizole A Liquid | Boehringer lngelheim Animal Health USA Inc. | 2 |
| TBZ Wormer Paste 50% | Boehringer lngelheim Animal Health USA Inc. | 1 |
| TBZ Wormer Paste 43% | Boehringer lngelheim Animal Health USA Inc. | 1 |
| Equivet-14, Equizole-B | Farnam Companies Inc. | 2 |
| Equizole 50% Wormer Paste, Equizole 50% Wormer Paste For Horses | Boehringer lngelheim Animal Health USA Inc. | 1 |
| Thiabendazole, Dexamethasone, Neomycin Sulfate Solution | Dechra Veterinary Products LLC | 3 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 11.12 | acidic |
| pKa2 | 4.62 | Basic |
| pKa3 | 1.83 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Histone deacetylase 6 | Enzyme | IC50 | 6.44 | CHEMBL | |||||
| Methionine aminopeptidase 2 | Enzyme | IC50 | 4.35 | CHEMBL | |||||
| Peptidyl-prolyl cis-trans isomerase FKBP1A | Enzyme | Kd | 4.22 | CHEMBL | |||||
| Methionine aminopeptidase 1 | Enzyme | EC50 | 5.47 | CHEMBL | |||||
| Cytochrome P450 1A2 | Enzyme | IC50 | 6.10 | DRUG MATRIX | |||||
| Tubulin | Structural | INHIBITOR | CHEMBL | CHEMBL | |||||
| Tubulin | Structural | INHIBITOR | CHEMBL | CHEMBL | |||||
| Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial | Enzyme | WOMBAT-PK | |||||||
| Methionine aminopeptidase | Enzyme | IC50 | 6.33 | CHEMBL | |||||
| Reverse transcriptase/RNaseH | Enzyme | IC50 | 4.84 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4017955 | VUID |
| N0000146305 | NUI |
| D00372 | KEGG_DRUG |
| 4017955 | VANDF |
| C0039832 | UMLSCUI |
| CHEBI:45979 | CHEBI |
| CHEMBL625 | ChEMBL_ID |
| DB00730 | DRUGBANK_ID |
| D013827 | MESH_DESCRIPTOR_UI |
| 5430 | PUBCHEM_CID |
| 7304 | IUPHAR_LIGAND_ID |
| 1436 | INN_ID |
| N1Q45E87DT | UNII |
| 10450 | RXNORM |
| 1245 | MMSL |
| 5565 | MMSL |
| 80871 | MMSL |
| d00160 | MMSL |
| 002985 | NDDF |
| 36594001 | SNOMEDCT_US |
| 416624006 | SNOMEDCT_US |
| TMG | PDB_CHEM_ID |
| N1Q45E87DT | INXIGHT DRUGS |
Pharmaceutical products:
None